A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight

NCT ID: NCT05567796

Last Updated: 2025-12-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE3

Total Enrollment

3400 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-11-01

Study Completion Date

2026-10-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study has 2 parts: First part is the main study and second part is the extension study. During the main study participants will receive 1 of 4 study medicines. If participants continue in the extension study, they will not receive any study medicine during the extension. The main study will look at how well CagriSema helps participants with excess body weight lose weight compared to a "dummy" medicine and 2 other medicines, cagrilintide and semaglutide. Participants will either get CagriSema, cagrilintide,semaglutide or "dummy" medicine. Which treatment participants get is decided by chance. They will take one injection once a week. The study medicine is injected briefly with a thin needle, typically in the stomach, thighs or upper arms.

Extension study: After the main study, not all participants will continue in the extension study. The study staff will tell the participant if they will continue or not into the extension study. In the extension study we will look at what happens to the participant's body weight and diseases related to excess body weight after the participant stops taking the study medicine. The main study will last for about 1½ years and the extension study will last for another 2 years.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cagrisema

Participants will receive cagrilintide and semaglutide once-weekly after a dose escalation period of 16 weeks during the maintenance period for 52 weeks in the main phase. Participants randomised to this arm will be included in the extension phase for 97 weeks.

Group Type EXPERIMENTAL

Cagrilintide

Intervention Type DRUG

Cagrilintide will be administered subcutaneously.

Semaglutide

Intervention Type DRUG

Participants will recieve semaglutide subcutaneously.

Cagrilintide

Participants will receive cagrilintide s.c. and placebo matching to semaglutide once-weekly after a dose escalation period of 16 weeks during the maintenance period for 52 weeks.

Group Type ACTIVE_COMPARATOR

Cagrilintide

Intervention Type DRUG

Cagrilintide will be administered subcutaneously.

Placebo semaglutide

Intervention Type DRUG

Participants will receive placebo matched to semaglutide.

Semaglutide

Participants will receive semaglutide s.c.and placebo matched to cagrilintide once-weekly after a dose escalation period of 16 weeks during the maintenance period for 52 weeks.

Group Type ACTIVE_COMPARATOR

Semaglutide

Intervention Type DRUG

Participants will recieve semaglutide subcutaneously.

Placebo cagrilintide

Intervention Type DRUG

Participants will receive placebo matched to cagrilintide.

Placebo s.c.

Participants will receive placebo matched to cagrilintide and placebo matched to semaglutide once weekly for 68 weeks. Participants randomised to this arm will be included in the extension phase for 97 weeks.

Group Type PLACEBO_COMPARATOR

Placebo cagrilintide

Intervention Type DRUG

Participants will receive placebo matched to cagrilintide.

Placebo semaglutide

Intervention Type DRUG

Participants will receive placebo matched to semaglutide.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cagrilintide

Cagrilintide will be administered subcutaneously.

Intervention Type DRUG

Semaglutide

Participants will recieve semaglutide subcutaneously.

Intervention Type DRUG

Placebo cagrilintide

Participants will receive placebo matched to cagrilintide.

Intervention Type DRUG

Placebo semaglutide

Participants will receive placebo matched to semaglutide.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female
* Age above or equal to 18 years at the time of signing informed consent
* Body mass index (BMI) greater than or equal to 30.0 kilograms per square meter (kg/m\^2) or b) BMI greater than or equal to 27.0 kg/m\^2 with the presence of at least one weight-related comorbidity including, but not limited to hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease

Exclusion Criteria

\- Glycaemia related: a) Glycated Haemoglobin (HbA1c) greater than or equal to 6.5 percent (48 millimoles per mole \[mmol/mol\]) as measured by the central laboratory at screening b) History of type 1 or type 2 diabetes mellitus
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Novo Nordisk A/S

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Clinical Transparency (dept. 2834)

Role: STUDY_DIRECTOR

Novo Nordisk A/S

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Univ of Alabama Birmingham

Birmingham, Alabama, United States

Site Status

Velocity Clin Res Los Angeles

Los Angeles, California, United States

Site Status

Velocity Clin Res Wstlke

Los Angeles, California, United States

Site Status

Univ of Colorado at Denver

Aurora, Colorado, United States

Site Status

New West Physicians,Inc.

Golden, Colorado, United States

Site Status

Northeast Research Institute

Fleming Island, Florida, United States

Site Status

South Broward Research LLC

Miramar, Florida, United States

Site Status

Clinical Neuroscience Solution

Orlando, Florida, United States

Site Status

Florida Inst For Clin Res

Orlando, Florida, United States

Site Status

Clinical Trial Res Assoc,Inc

Plantation, Florida, United States

Site Status

Hope Clin Res & Wellness

Conyers, Georgia, United States

Site Status

East West Med Res Inst

Honolulu, Hawaii, United States

Site Status

Great Lakes Clinical Trials

Chicago, Illinois, United States

Site Status

Endeavor Health

Skokie, Illinois, United States

Site Status

Evanston Premier Hlthcr Res

Skokie, Illinois, United States

Site Status

Midwest Inst For Clin Res

Indianapolis, Indiana, United States

Site Status

Northern Pines Hlth Ctr, PC

Buckley, Michigan, United States

Site Status

StudyMetrix Research LLC

City of Saint Peters, Missouri, United States

Site Status

Velocity Clinical Research Binghamton

Binghamton, New York, United States

Site Status

Comprehensive Weight Ctrl Prog

New York, New York, United States

Site Status

University of North Carolina

Chapel Hill, North Carolina, United States

Site Status

Medication Mgmnt, LLC_Grnsboro

Greensboro, North Carolina, United States

Site Status

PharmQuest Life Sciences LLC

Greensboro, North Carolina, United States

Site Status

Accellacare_NC

Raleigh, North Carolina, United States

Site Status

Accellacare

Wilmington, North Carolina, United States

Site Status

New Venture Medical Research

Wadsworth, Ohio, United States

Site Status

Lynn Institute of Norman

Norman, Oklahoma, United States

Site Status

The University of Penn Center

Philadelphia, Pennsylvania, United States

Site Status

Clinical Res Collaborative

Cumberland, Rhode Island, United States

Site Status

Medical Uni of SC Charleston

Charleston, South Carolina, United States

Site Status

Coastal Carolina Res Ctr

North Charleston, South Carolina, United States

Site Status

Hillcrest Clinical Research

Simpsonville, South Carolina, United States

Site Status

Spartanburg Medical Research

Spartanburg, South Carolina, United States

Site Status

Holston Medical Group_Bristol

Bristol, Tennessee, United States

Site Status

Holston Medical Group

Kingsport, Tennessee, United States

Site Status

Baylr Sctt White Rs Inst, Endo

Dallas, Texas, United States

Site Status

Velocity Clinical Res-Dallas

Dallas, Texas, United States

Site Status

UT Southwestern Med Cntr

Dallas, Texas, United States

Site Status

DCOL Ctr for Clin Res

Longview, Texas, United States

Site Status

Washington Cntr Weight Mgmt

Arlington, Virginia, United States

Site Status

Health Res of Hampton Roads

Newport News, Virginia, United States

Site Status

Selma Medical Associates

Winchester, Virginia, United States

Site Status

Capital Clin Res Ctr,LLC

Olympia, Washington, United States

Site Status

Rainier Clin Res Ctr Inc

Renton, Washington, United States

Site Status

Fundación CESIM

Santa Rosa, La Pampa Province, Argentina

Site Status

CEDIC Centro de Investigación Clínica

CABA, , Argentina

Site Status

Centro de Investigación Clínica

CABA, , Argentina

Site Status

Centro Médico Viamonte SRL

CABA, , Argentina

Site Status

Instituto Centenario

Ciudad de Buenos Aires, , Argentina

Site Status

Sanatorio Norte

Santiago del Estero, , Argentina

Site Status

Northern Beaches Clinical Research

Brookvale, New South Wales, Australia

Site Status

Novatrials

Charlestown, New South Wales, Australia

Site Status

Momentum Clinical Research Darlinghurst

Darlinghurst, New South Wales, Australia

Site Status

Momentum Clinical Research

Taringa, Queensland, Australia

Site Status

Imeldaziekenhuis - Bonheiden - Department of Endocrinology

Bonheiden, , Belgium

Site Status

CHR Mons-Hainaut - Site Warquignies

Boussu, , Belgium

Site Status

Cliniques Universitaires Saint-Luc - Serv Endocrinologie - Diabétologie

Brussels, , Belgium

Site Status

UZ Antwerpen - UZA - Department of Endocrinology

Edegem, , Belgium

Site Status

UZA - UZ Antwerpen - Department of Endocrinology

Edegem, , Belgium

Site Status

UZ Gent - Endocrinologie

Ghent, , Belgium

Site Status

UZ Leuven - Endocrinology

Leuven, , Belgium

Site Status

CHU Helora - Hôpital de Mons - Site Constantinople

Mons, , Belgium

Site Status

Medical centre Asclepius OOD

Dupnitsa, Kyustendil, Bulgaria

Site Status

"Multiprofile hospital for active treatment Puls" AD

Blagoevgrad, , Bulgaria

Site Status

OCIPSOMC - Endocrinology NT EOOD

Montana, , Bulgaria

Site Status

OCSOMCE - Dr. Albena Dinkova EOOD

Pleven, , Bulgaria

Site Status

DCC Iztok EOOD

Plovdiv, , Bulgaria

Site Status

ASOMCEM - Individual Practice - Dr. Antoanela Slavcheva

Rousse, , Bulgaria

Site Status

ASOMCEM - IP - Dr. Antoanela Slavcheva

Rousse, , Bulgaria

Site Status

Nader Yabrudi - ASMPVBE Individual practice

Smolyan, , Bulgaria

Site Status

UMHAT "Aleksandrovska"

Sofia, , Bulgaria

Site Status

USHATE "Acad. Ivan Penchev" First Clinic of Endocrinology

Sofia, , Bulgaria

Site Status

USHATE "Akad. Ivan Penchev" Second Clinic of Endocrinology

Sofia, , Bulgaria

Site Status

DCC XVIII - Sofia EOOD

Sofia, , Bulgaria

Site Status

"UMHAT "Tsaritsa Yoanna-ISUL"" EAD, Clinic of endocrinology and metabolic disease for metabolic disorders treatment

Sofia, , Bulgaria

Site Status

"DCC XX - Sofia" EOOD, Endocrinology Consulting Room

Sofia, , Bulgaria

Site Status

AIPSMC Dr. Artin Magardichyan EOOD

Varna, , Bulgaria

Site Status

Medical center Berbatov

Yambol, , Bulgaria

Site Status

C-endo Diab & Endo Clinic

Edmonton, Alberta, Canada

Site Status

Synergy Wellness Clinic

Sherwood Park, Alberta, Canada

Site Status

Ocean West Research Clinic

Surrey, British Columbia, Canada

Site Status

Dr. M.B. Jones Inc

Victoria, British Columbia, Canada

Site Status

G.A. Research Associates Ltd.

Moncton, New Brunswick, Canada

Site Status

Nova Scotia Hlth Halifax

Halifax, Nova Scotia, Canada

Site Status

Premier Clinical Trial Research Network (PCTRN)

Hamilton, Ontario, Canada

Site Status

Aarhus Universitetshospital Diabetes og Hormonsygdomme

Aarhus N, , Denmark

Site Status

Sydvestjysk Sygehus Esbjerg

Esbjerg, , Denmark

Site Status

Center for Klinisk Metabolisk Forskning

Hellerup, , Denmark

Site Status

Gentofte Hospital - Center for Klinisk Metabolisk Forskning

Hellerup, , Denmark

Site Status

Hvidovre Hospital Endokrinologisk forsknings afsnit 159

Hvidovre, , Denmark

Site Status

Sjællands Universitetshospital, Køge - Medicinsk Afdeling

Køge, , Denmark

Site Status

Sjællands Universitetshospital

Køge, , Denmark

Site Status

HUS Clinical Research Biomedicum 2U

Helsinki, , Finland

Site Status

Health Step Finland Oy

Kuopio, , Finland

Site Status

OYS - Sisätautien tutkimusyksikkö

Oulu, , Finland

Site Status

Turku University Hospital

Turku, , Finland

Site Status

Aphp-Hopital La Pitie Salpetriere-3

Paris, , France

Site Status

Hospices Civils de Lyon-Hopital Lyon Sud-1

Pierre-Bénite, , France

Site Status

Centre Hospitalier Universitaire de Nantes-Hopital Nord Laennec-1

Saint-Herblain, , France

Site Status

Les Hopitaux Universitaires de Strasbourg-Hopital de Hautepierre-1

Strasbourg, , France

Site Status

Centre de Recherche Clinique Portes Du Sud

Vénissieux, , France

Site Status

Diabetespraxis Mergentheim

Bad Mergentheim, , Germany

Site Status

Zentrum fuer klinische Studien Suedbrandenburg GmbH

Elsterwerda, , Germany

Site Status

InnoDiab Forschung GmbH

Essen, , Germany

Site Status

Wendisch/Dahl Hamburg (DZHW)

Hamburg, , Germany

Site Status

Uniklinik Leipzig - Klinik und Poliklinik für Endokrinologie, Nephrologie, Rheumatologie

Leipzig, , Germany

Site Status

AmBeNet GmbH

Leipzig, , Germany

Site Status

Institut für Diabetesforschung GmbH Münster - Dr. med. Rose

Münster, , Germany

Site Status

MZM Praxis Drs. Erlinger

Stuttgart, , Germany

Site Status

Zentrum für klinische Studien Allgäu Oberschwaben

Wangen, , Germany

Site Status

Nirmal Hospital Pvt. Ltd.

Surat, Gujarat, India

Site Status

Belgaum Diabetes Centre

Belagavi, Karnataka, India

Site Status

Government Medical College, Kozhikode

Kozhikode, Kerala, India

Site Status

Sir H. N. Reliance Foundation Hospital and Research Centre

Mumbai, Maharashtra, India

Site Status

Wockhardt Hospital, Mumbai Central

Mumbai, Maharashtra, India

Site Status

Government Medical College and Super Speciality Hospital, Nagpur

Nagpur, Maharashtra, India

Site Status

Grant Medical Foundation Ruby Hall Clinic

Pune, Maharashtra, India

Site Status

Deenanath Mangeshkar Hospital & Research Centre

Pune, Maharashtra, India

Site Status

Sahyadri Super Speciality Hospital

Pune, Maharashtra, India

Site Status

Chellaram Diabetes Institute

Pune, Maharashtra, India

Site Status

chelleram Diabetes Institute

Pune, Maharashtra, India

Site Status

Maulana Azad Medical College

Delhi, New Delhi, India

Site Status

Post Graduate Institute of Medical Education & Research_Chandigarh

Chandigarh, Punjab, India

Site Status

SMS Medical College & Hospital

Jaipur, Rajasthan, India

Site Status

Eternal Heart Care Centre

Jaipur, Rajasthan, India

Site Status

Christian Medical College Hospital, Vellore

Vellore, Tamil Nadu, India

Site Status

AIG Hospitals,Hyderabad

Hyderabad, Telangana, India

Site Status

All India Institute of Medical Sciences_New Dehli

Delhi, , India

Site Status

Osmania General Hospital

Hyderabad, , India

Site Status

A.O.U. Consorziale Policlinico di Bari

Bari, BA, Italy

Site Status

Azienda Ospedaliero-Universitaria Renato Dulbecco

Catanzaro, Cz, Italy

Site Status

Policlinico San Donato S.p.A.

San Donato Milanese (MI), Lombardy, Italy

Site Status

Pol. Uni. Campus Biomedico

Roma, RM, Italy

Site Status

Azienda Ospedaliera Universitaria Senese

Siena, SI, Italy

Site Status

A.O.Universitaria S.ORSOLA-MALPIGHI - U.O.Endocrinologia e Cura

Bologna, , Italy

Site Status

ARNAS Garibaldi Catania - Presidio Ospedaliero Garibaldi-Centro

Catania, , Italy

Site Status

Azienda Ospedaliera di Padova Clin.Med.3

Padua, , Italy

Site Status

Ospedale Civico Partinico di Palermo

Partinico, , Italy

Site Status

Policlinico Universitario Tor Vergata

Roma, , Italy

Site Status

Azienda Ospedaliera Universitaria Policlinico Umberto I

Roma, , Italy

Site Status

Shinsapporo Seiryou Hospital_General Clinical Department

Sapporo, Hokkaido, Japan

Site Status

OCROM Clinic_Internal medicine

Suita-shi, Osaka, Japan

Site Status

TOSAKI Clinic for Diabetes and Endocrinology_Diabetes and Endocrinology

Aichi, , Japan

Site Status

Chiba University Hospital_Diabetes, Metabolism and Endocrinology

Chiba-shi, Chiba, , Japan

Site Status

Kawada Clinic

Gunma, , Japan

Site Status

Motomachi Takatsuka Naika Clinic_Internal Medicine

Kanagawa, , Japan

Site Status

Osaka NISHI-UMEDA Clinic_Internal Medicine

Osaka, , Japan

Site Status

Asano Clinic

Saitama, , Japan

Site Status

Shinden Higashi Clinic

Sendai-shi, Miyagi, , Japan

Site Status

Tokyo-Eki Center-building Clinic_Internal Medicine

Tokyo, , Japan

Site Status

Tokyo-Eki Center-building Clinic

Tokyo, , Japan

Site Status

Fukuwa Clinic_Internal Medicine

Tokyo, , Japan

Site Status

Miho Clinic

Tokyo, , Japan

Site Status

ToCROM Clinic_Internal Medicine

Tokyo, , Japan

Site Status

Higashi-shinjuku clinic

Tokyo, , Japan

Site Status

Consultorio Arechavaleta Granell María del Rosario

Guadalajara, Jalisco, Mexico

Site Status

Centro de Investigacion Clinica Endocrinologica de Jalisco

Guadalajara, Jalisco, Mexico

Site Status

Internal Medicine Clin Trials

Monterrey, Nuevo León, Mexico

Site Status

Cardiolink Clin Trials S.C.

Monterrey, Nuevo León, Mexico

Site Status

Centro de Investigación Cardiometabólica de Aguascalientes

Aguascalientes, , Mexico

Site Status

Academisch Medisch Centrum

Amsterdam, , Netherlands

Site Status

Rijnstate Ziekenhuis

Arnhem, , Netherlands

Site Status

Spaarne Gasthuis_Hoofddorp

Hoofddorp, , Netherlands

Site Status

Bravis Ziekenhuis

Roosendaal, , Netherlands

Site Status

Albert Schweitzer Ziekenhuis, locatie Zwijndrecht

Zwijndrecht, , Netherlands

Site Status

50BIO.COM Sp. z o.o.

Bydgoszcz, Kujawsko-Pomorskie Voivodeship, Poland

Site Status

Gierach-Med

Bygdoszcz, Kuyavian-Pomeranian Voivodeship, Poland

Site Status

Centrum Medyczne Plejady

Krakow, Lesser Poland Voivodeship, Poland

Site Status

Beata Miklaszewicz & Dariusz Dabrowski "CARDIAMED" s.j.

Legnica, Lower Silesian Voivodeship, Poland

Site Status

Terpa Sp. z o.o. Sp. k.

Lublin, Lubelskie Voivodeship, Poland

Site Status

Samodzielny Publiczny Szpital Kliniczny Im. Prof. W. Orłowskiego Centrum Medycznego Kształcenia Podyplomowego

Warsaw, Masovian Voivodeship, Poland

Site Status

Instytut Diabetologii Sp. z o.o.

Warsaw, Mazovian Voivodeship, Poland

Site Status

Uniwersytecki Szpital Kliniczny w Bialymstoku

Bialystok, Podlaskie Voivodeship, Poland

Site Status

Gabinet Leczenia Otylosci i Chorob Dietozaleznych

Bialystok, Podlaskie Voivodeship, Poland

Site Status

NZOZ Vita-Diabetica Malgorzata Buraczyk

Bialystok, Podlaskie Voivodeship, Poland

Site Status

Uniwersyteckie Centrum Kliniczne

Gdansk, Pomeranian Voivodeship, Poland

Site Status

Centrum Medyczne Salvia

Katowice, Slaskie Voivodeship, Poland

Site Status

Klinika Bellamed

Elblag, Warmian-Masurian Voivodeship, Poland

Site Status

Centrum Ginekologii, Poloznictwa i Leczenia Nieplodnosci

Poznan, Wielkopolskie Voivodeship, Poland

Site Status

Centrum Ginekologii, Położnictwa i Leczenia Niepłodności

Poznan, Wielkopolskie Voivodeship, Poland

Site Status

Centrum Zdrowia Metabolicznego

Poznan, Wielkopolskie Voivodeship, Poland

Site Status

Centrum Medyczne Plejady

Krakow, , Poland

Site Status

Beata Mikłaszewicz & Dariusz Dąbrowski "CARDIAMED" s.j.

Legnica, , Poland

Site Status

Terpa Sp. z o.o. Sp. k.

Lublin, , Poland

Site Status

Samodzielny Publiczny Szpital Kliniczny Im. Prof. W. Orłowskiego Centrum Medycznego Kształcenia Podyplomowego

Warsaw, , Poland

Site Status

Instytut Diabetologii Sp. z o.o.

Warsaw, , Poland

Site Status

Clin. Centre Vojvodina, Clin. endocr., diab. and met. dis.

Novi Sad, Vojvodina, Serbia

Site Status

Endocrinology, Diabetes and Metabolism Diseases Clinic

Belgrade, , Serbia

Site Status

Clinical Hospital Center Bezanijska Kosa

Belgrade, , Serbia

Site Status

Clin. Centre Vojvodina, Clin. endocr., diab. and met. dis.

Novi Sad, , Serbia

Site Status

East Rand Physicians

Benoni, Gauteng, South Africa

Site Status

Dr R Dulabh

Johannesburg, Gauteng, South Africa

Site Status

Dr Moosa's Rooms

Lenasia, Gauteng, South Africa

Site Status

Shop#1 Health Emporium

Midrand, Gauteng, South Africa

Site Status

Botho ke Bontle Health Services

Pretoria, Gauteng, South Africa

Site Status

Dr Vawda's site

Durban, KwaZulu-Natal, South Africa

Site Status

Dr J Reddy

Durban, KwaZulu-Natal, South Africa

Site Status

Armansis Medical Centre

Brits, North West, South Africa

Site Status

Dr Hilton Kaplan

Cape Town, Western Cape, South Africa

Site Status

The Catholic University of Korea, Bucheon ST. Mary's Hospital

Bucheon-si, Gyeonggi-do, South Korea

Site Status

The catholic university of Korea, Bucheon St.Mary's Hospital

Bucheon-si, Gyeonggi-do, South Korea

Site Status

Kyungpook National University Hospital

Daegu, , South Korea

Site Status

Daejeon Eulji Medical Center, Eulji University

Daejeon, , South Korea

Site Status

Gachon University Gil Medical Center

Incheon, , South Korea

Site Status

Seoul National University Bundang Hospital

Seongnam-si, Gyeonggi-do, , South Korea

Site Status

Seoul National University Hospital

Seoul, , South Korea

Site Status

Severance Hospital, Yonsei University Health System

Seoul, , South Korea

Site Status

Asan Medical Center

Seoul, , South Korea

Site Status

Samsung Medical Center

Seoul, , South Korea

Site Status

Pusan National University Yangsan Hospital

Yangsan, , South Korea

Site Status

Clinica Universitaria de Navarra

Pamplona, Navarre, Spain

Site Status

Hospital Clinic i Provincial

Barcelona, , Spain

Site Status

Hospital de León

León, , Spain

Site Status

Hospital de León

León, , Spain

Site Status

Hospital Gregorio Marañón

Madrid, , Spain

Site Status

Clínica Nuevas Tecnologías en Diabetes y Endocrinología

Seville, , Spain

Site Status

Hospital Infanta Luisa

Seville, , Spain

Site Status

Hospital Vithas Sevilla

Seville, , Spain

Site Status

China Medical University Hospital

Taichung, , Taiwan

Site Status

National Taiwan University Hospital_main

Taipei, , Taiwan

Site Status

Baskent University Ankara Hospital

Ankara, Cankaya, Turkey (Türkiye)

Site Status

Başkent Üniversitesi Ankara Hastanesi-Aile Hekimliği

Ankara, Cankaya, Turkey (Türkiye)

Site Status

Haseki Egitim ve Arastirma Hastanesi

Sultangazi, Istanbul, Turkey (Türkiye)

Site Status

Adana Şehir Eğitim ve Araştırma Hastanesi

Adana, , Turkey (Türkiye)

Site Status

Başkent Üniversitesi Adana Dr. Turgut Noyan Uygulama ve Araştırma Merkezi

Adana, , Turkey (Türkiye)

Site Status

Ankara Bilkent Şehir Hastanesi-Dahiliye

Ankara, , Turkey (Türkiye)

Site Status

Ankara Sehir Hastanesi Dahiliye Klinigi

Ankara, , Turkey (Türkiye)

Site Status

Akdeniz Üniversitesi Hastanesi- Endokrinoloji

Antalya, , Turkey (Türkiye)

Site Status

Hatay Mustafa Kemal Universitesi Saglik Uygulama ve Arastirm

Hatay, , Turkey (Türkiye)

Site Status

Istanbul Universitesi Istanbul Tip Fakultesi - Endokrinoloji

Istanbul, , Turkey (Türkiye)

Site Status

İstanbul Üniversitesi İstanbul Tıp Fakültesi Hastanesi- Endokrinoloji

Istanbul, , Turkey (Türkiye)

Site Status

Prof. Dr. Cemil Taşcıoğlu Şehir Hastanesi- Endokrinoloji

Istanbul, , Turkey (Türkiye)

Site Status

Haydarpaşa Numune Eğitim ve Araştırma Hastanesi - Endokrinoloji

Istanbul, , Turkey (Türkiye)

Site Status

Göztepe Prof. Dr.Süleyman Yalçın Şehir Hastanesi- Dahiliye

Istanbul, , Turkey (Türkiye)

Site Status

Sivas Cumhuriyet Univesity Endocrinology Department

Sivas, , Turkey (Türkiye)

Site Status

Sivas Cumhuriyet Üniversitesi Hastanesi -Endokrinoloji

Sivas, , Turkey (Türkiye)

Site Status

Princess Royal University Hospital

Orpington, Kent, United Kingdom

Site Status

Layton Medical Centre

Blackpool, , United Kingdom

Site Status

Southmead Hospital

Bristol, , United Kingdom

Site Status

Addenbrooke's Hospital_Cambridge

Cambridge, , United Kingdom

Site Status

Countess of Chester Hospital

Chester, , United Kingdom

Site Status

Hathaway Medical Centre

Chippenham, , United Kingdom

Site Status

University Hospital Coventry - WISDEM Centre

Coventry, , United Kingdom

Site Status

Aintree University Hospital

Liverpool, , United Kingdom

Site Status

University Hospital Aintree

Liverpool, , United Kingdom

Site Status

Guys Hospital

London, , United Kingdom

Site Status

Imperial College London

London, , United Kingdom

Site Status

UCL - Obesity

London, , United Kingdom

Site Status

Princess Royal University Hospital

Orpington, , United Kingdom

Site Status

Musgrove Park Hospital

Taunton, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Australia Belgium Bulgaria Canada Denmark Finland France Germany India Italy Japan Mexico Netherlands Poland Serbia South Africa South Korea Spain Taiwan Turkey (Türkiye) United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Verma S, Bottcher M, Brown P, Dicker D, Rubino D, Sbraccia P, Sharma AM, Smedegaard L, Sorrig R, Garvey WT. CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1. Hypertension. 2025 Dec 2. doi: 10.1161/HYPERTENSIONAHA.125.26055. Online ahead of print.

Reference Type DERIVED
PMID: 41328546 (View on PubMed)

Garvey WT, Bluher M, Osorto Contreras CK, Davies MJ, Winning Lehmann E, Pietilainen KH, Rubino D, Sbraccia P, Wadden T, Zeuthen N, Wilding JPH; REDEFINE 1 Study Group. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2025 Aug 14;393(7):635-647. doi: 10.1056/NEJMoa2502081. Epub 2025 Jun 22.

Reference Type DERIVED
PMID: 40544433 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Universal Trial Number (UTN)

Identifier Type: OTHER

Identifier Source: secondary_id

2020-005435-75

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

NN9838-4608

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.